{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:19:31Z","timestamp":1794932371738,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341203"],"award-info":[{"award-number":["82341203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01611-z","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T10:02:22Z","timestamp":1727517742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting GPRC5D for multiple myeloma therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Dian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"5","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"9","key":"1611_CR2","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"15","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80(15):1607\u201313.","journal-title":"Drugs"},{"issue":"12","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009;15(12):4028\u201337.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","volume":"8","author":"KR Kelly","year":"2021","unstructured":"Kelly KR, Ailawadhi S, Siegel DS, et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study. Lancet Haematol. 2021;8(11):e794\u2013807.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1611_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMe2209692","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Landgren O. T-cell engagers\u2014modern immune-based therapies for multiple myeloma. N Engl J Med. 2022;387(6):558\u201361.","journal-title":"N Engl J Med"},{"issue":"8","key":"1611_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775\u201383.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ, et al. Bispecific Antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423\u201333.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol. 2022;15(1):78.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","volume":"34","author":"N Gagelmann","year":"2020","unstructured":"Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317\u201332.","journal-title":"Leukemia"},{"issue":"13","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"1611_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","volume":"76","author":"K McKeage","year":"2016","unstructured":"McKeage K. Daratumumab: first global approval. Drugs. 2016;76(2):275\u201381.","journal-title":"Drugs"},{"issue":"18","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"1611_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"1611_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"14","key":"1611_CR17","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","volume":"30","author":"K Natrajan","year":"2024","unstructured":"Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR. FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(14):2865\u201371.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1611_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Teclistamab: first approval. Drugs. 2022;82(16):1613\u20139.","journal-title":"Drugs"},{"issue":"9","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"17","key":"1611_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S. Elranatamab: first approval. Drugs. 2023;83(17):1621\u20137.","journal-title":"Drugs"},{"issue":"52","key":"1611_CR21","doi-asserted-by":"publisher","first-page":"35008","DOI":"10.1074\/jbc.273.52.35008","volume":"273","author":"Y Cheng","year":"1998","unstructured":"Cheng Y, Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem. 1998;273(52):35008\u201315.","journal-title":"J Biol Chem"},{"issue":"2","key":"1611_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/geno.2000.6164","volume":"65","author":"H Brauner-Osborne","year":"2000","unstructured":"Brauner-Osborne H, Krogsgaard-Larsen P. Sequence and expression pattern of a novel human orphan G-protein-coupled receptor, GPRC5B, a family C receptor with a short amino-terminal domain. Genomics. 2000;65(2):121\u20138.","journal-title":"Genomics"},{"issue":"1","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/geno.2000.6226","volume":"67","author":"MJ Robbins","year":"2000","unstructured":"Robbins MJ, Michalovich D, Hill J, et al. Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics. 2000;67(1):8\u201318.","journal-title":"Genomics"},{"issue":"3","key":"1611_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","volume":"1518","author":"H Br\u00e4uner-Osborne","year":"2001","unstructured":"Br\u00e4uner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O\u2019Hara P. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001;1518(3):237\u201348.","journal-title":"Biochim Biophys Acta"},{"issue":"485","key":"1611_CR25","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Investig Dermatol. 2004;122(3):565\u201373.","journal-title":"J Investig Dermatol"},{"issue":"15","key":"1611_CR27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendonca M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"issue":"2_suppl","key":"1611_CR28","doi-asserted-by":"publisher","first-page":"s91","DOI":"10.1016\/S2152-2650(21)02229-1","volume":"21","author":"R Goldsmith","year":"2021","unstructured":"Goldsmith R, Cornax I, Ma J, Yao X, Peng P, Carreira V. Normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for Multiple Myeloma, is restricted to plasma cells and hard keratinized tissues. Clin Lymphoma Myeloma. 2021;21(2_suppl):s91.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","volume":"18","author":"Y Cohen","year":"2013","unstructured":"Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 2013;18(6):348\u201351.","journal-title":"Hematology"},{"issue":"21","key":"1611_CR30","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood.V122.21.3099.3099","volume":"122","author":"SU Venkateshaiah","year":"2013","unstructured":"Venkateshaiah SU, Bam R, Li X, et al. GPRC5D is a cell surface plasma cell marker whose expression is high in myeloma cells and reduced following coculture with osteoclasts. Blood. 2013;122(21):3099.","journal-title":"Blood"},{"issue":"8","key":"1611_CR31","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"issue":"9","key":"1611_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Investig. 2012;42(9):953\u201360.","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"1611_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12(1):44.","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"1611_CR34","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger MS, Duell J, Zhou X, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021;5(19):3794\u20138.","journal-title":"Blood Adv"},{"issue":"9","key":"1611_CR35","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"11","key":"1611_CR36","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, Gastineau S, Frigout A, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4(11):1536\u201343.","journal-title":"Nat Cancer"},{"issue":"15","key":"1611_CR37","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMc2308544","volume":"389","author":"X Mi","year":"2023","unstructured":"Mi X, Penson A, Abdel-Wahab O, Mailankody S. Genetic basis of relapse after GPRC5D-targeted CAR T cells. N Engl J Med. 2023;389(15):1435\u20137.","journal-title":"N Engl J Med"},{"issue":"13","key":"1611_CR38","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"6","key":"1611_CR39","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38(6):1323\u201333.","journal-title":"Leukemia"},{"key":"1611_CR40","doi-asserted-by":"publisher","unstructured":"Papadimitriou M, Ahn S, Diamond B, et al. Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies. bioRxiv. 2024;https:\/\/doi.org\/10.1101\/2024.05.22.595383","DOI":"10.1101\/2024.05.22.595383"},{"issue":"13","key":"1611_CR41","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","volume":"128","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735\u201344.","journal-title":"Blood"},{"issue":"24","key":"1611_CR42","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.3390\/cancers15245774","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhou YQ, Nie L, et al. BR109, a novel fully humanized T-cell-engaging bispecific antibody with GPRC5D binding, has potent antitumor activities in multiple myeloma. Cancers (Basel). 2023;15(24):5774.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1611_CR43","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41(14):2583\u201393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1611_CR44","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107\u201316.","journal-title":"Lancet Haematol"},{"issue":"24","key":"1611_CR45","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"15","key":"1611_CR46","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Talquetamab: first approval. Drugs. 2023;83(15):1439\u201345.","journal-title":"Drugs"},{"issue":"9","key":"1611_CR47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"1_suppl","key":"1611_CR48","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2023-181613","volume":"142","author":"J Fu","year":"2023","unstructured":"Fu J, Jiang L, Zhu Z, et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells. Blood. 2023;142(1_suppl):4802.","journal-title":"Blood"},{"issue":"1","key":"1611_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","volume":"16","author":"R Huang","year":"2023","unstructured":"Huang R, Wen Q, Zhang X. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol. 2023;16(1):35.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1611_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146\u201354.","journal-title":"Blood Cancer Discov"},{"key":"1611_CR51","unstructured":"Du J, He H, Jin L, et al. First-in-human study of GPRC5D-targeyed CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed\/refractory multiple myeloma (RRMM). HemaSphere. HemaSphere. 2024. https:\/\/library.ehaweb.org\/."},{"issue":"16_suppl","key":"1611_CR52","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8036.","journal-title":"J Clin Oncol"},{"key":"1611_CR53","doi-asserted-by":"crossref","unstructured":"Rasche L, Schinke C, Touzeau C, et al. Long-term efficacy and safety results from the phase 1\/2 Monumental-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. HemaSphere. 2024. https:\/\/library.ehaweb.org\/.","DOI":"10.1016\/S2152-2650(24)00976-5"},{"key":"1611_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","volume":"6","author":"C Hasselbalch Riley","year":"2022","unstructured":"Hasselbalch Riley C, Hutchings M, Yoon SS, et al. RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial. HemaSphere. 2022;6:81\u20132.","journal-title":"HemaSphere"},{"issue":"1_suppl","key":"1611_CR55","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.1182\/blood-2022-158146","volume":"140","author":"I Dekhtiarenko","year":"2022","unstructured":"Dekhtiarenko I, Lelios I, Attig J, et al. Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed\/refractory multiple myeloma (RRMM): biomarker results from a phase I study. Blood. 2022;140(1_suppl):10137\u20139.","journal-title":"Blood"},{"issue":"1_suppl","key":"1611_CR56","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140(1_suppl):397\u20139.","journal-title":"Blood"},{"issue":"16_suppl","key":"1611_CR57","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","volume":"42","author":"H Huang","year":"2024","unstructured":"Huang H, Zhang M, Wei G, et al. OriCAR-017 a novel GPRC5D-targeting CAR-T in patients with relapsed refractory multiple myeloma long term follow-up results of phase 1 study. J Clin Oncol. 2024;42(16_suppl):7511.","journal-title":"J Clin Oncol"},{"issue":"1_suppl","key":"1611_CR58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal S, Htut M, Nadeem O, et al. BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 Study. Blood. 2023;142(1_suppl):219\u201321.","journal-title":"Blood"},{"issue":"1_suppl","key":"1611_CR59","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2023-179147","volume":"142","author":"S Li","year":"2023","unstructured":"Li S, Yuan Z, Liu L, et al. Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients. Blood. 2023;142(1_suppl):3472.","journal-title":"Blood"},{"key":"1611_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00176-5","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024. https:\/\/doi.org\/10.1016\/S2352-3026(24)00176-5.","journal-title":"Lancet Haematol"},{"issue":"1_suppl","key":"1611_CR61","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","volume":"140","author":"J Reiser","year":"2022","unstructured":"Reiser J, Chan SR, Mathavan K, et al. FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. Blood. 2022;140(1_suppl):4560\u20131.","journal-title":"Blood"},{"issue":"1_suppl","key":"1611_CR62","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1182\/blood-2022-159289","volume":"140","author":"Z Cao","year":"2022","unstructured":"Cao Z, Yang C, Wang Y, et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. Blood. 2022;140(1_suppl):7378.","journal-title":"Blood"},{"issue":"12_Suppl","key":"1611_CR63","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","volume":"82","author":"W Huang","year":"2022","unstructured":"Huang W, Luo J, Li Y, Fei D, Qin X, Li R. Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res. 2022;82(12_Suppl):6020.","journal-title":"Cancer Res"},{"issue":"1_Suppl","key":"1611_CR64","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","volume":"142","author":"AJ Jakubowiak","year":"2023","unstructured":"Jakubowiak AJ, Anguille S, Karlin L, et al. Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study. Blood. 2023;142(1_Suppl):3377.","journal-title":"Blood"},{"key":"1611_CR65","doi-asserted-by":"crossref","unstructured":"Qi Y, Li H, Qi K, et al. Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.\u00a0Am J Hematol. Published online August 28, 2024.","DOI":"10.21203\/rs.3.rs-4285766\/v1"},{"issue":"16_Suppl","key":"1611_CR66","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, et al. First results from the RedirecTT-1 study with teclistamab (tec)+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_Suppl):8002.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1611_CR67","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"KSM Rejeski","year":"2023","unstructured":"Rejeski KSM, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377.","journal-title":"Blood"},{"issue":"24","key":"1611_CR68","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138(24):2499\u2013513.","journal-title":"Blood"},{"issue":"1","key":"1611_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1611_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","volume":"21","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Kunz WG, Rudelius M, et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy\u2014a case report. BMC Infect Dis. 2021;21(1):121.","journal-title":"BMC Infect Dis"},{"issue":"20","key":"1611_CR71","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139.","journal-title":"Blood"},{"key":"1611_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"1611_CR73","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1611_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Perez A, Iacoboni G, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022;10(5): e004475.","journal-title":"J Immunother Cancer"},{"issue":"16_Suppl","key":"1611_CR75","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2023.41.16_suppl.8020","volume":"41","author":"P Rodr\u00edguez-Otero","year":"2023","unstructured":"Rodr\u00edguez-Otero P, Schinke CD, Chari A, et al. Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. J Clin Oncol. 2023;41(16_Suppl):8020.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1611_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"BZ Sim","year":"2023","unstructured":"Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023;13(1):34.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1611_CR77","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1611_CR78","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"1611_CR79","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1611_CR80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125.","journal-title":"J Hematol Oncol"},{"issue":"1_Suppl","key":"1611_CR81","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2019-129088","volume":"134","author":"L Mikkilineni","year":"2019","unstructured":"Mikkilineni L, Manasanch EE, Lam N, et al. T cells expressing an anti-B-Cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma. Blood. 2019;134(1_Suppl):3230.","journal-title":"Blood"},{"issue":"5","key":"1611_CR82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","volume":"20","author":"K Nath","year":"2023","unstructured":"Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol. 2023;20(5):281\u20132.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1611_CR83","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","volume":"16","author":"J Xia","year":"2023","unstructured":"Xia J, Li Z, Xu K. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023;16(1):60.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1611_CR84","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-023-00436-9","volume":"12","author":"J Hou","year":"2023","unstructured":"Hou J, Li Y, Lin Q. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Exp Hematol Oncol. 2023;12(1):74.","journal-title":"Exp Hematol Oncol"},{"issue":"16_Suppl","key":"1611_CR85","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","volume":"41","author":"BR Dholaria","year":"2023","unstructured":"Dholaria BR, Weisel K, Mateos MV, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. J Clin Oncol. 2023;41(16_Suppl):8003.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1611_CR86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1611_CR87","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283.","journal-title":"Nat Commun"},{"issue":"1","key":"1611_CR88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-024-00485-8","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Guo H, Han L, Song Y, Zhou K. Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):25.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1611_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol. 2023;16(1):92.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01611-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01611-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01611-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T11:03:00Z","timestamp":1727521380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01611-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01611-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}